Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody therapy targets blood cancers in early trial

NCT ID NCT05424822

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This early-phase study tests a new drug called JNJ-80948543 in people with non-Hodgkin lymphoma or chronic lymphocytic leukemia whose cancer has returned or not responded to other treatments. The drug works by redirecting the body's T-cells to attack cancer cells. The main goals are to check safety and find the best dose. About 167 participants will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell non-Hodgkin lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL LYMPHOMA, NON-HODGKIN

Contacts and locations

Locations

  • Aichi Cancer Center

    Nagoya, 464 8681, Japan

  • Aidport Sp z o o

    Skorzewo, 60-185, Poland

  • CHRU de Lille Hopital Claude Huriez

    Lille, 59037, France

  • Carmel Medical Center

    Haifa, 34362, Israel

  • Chongqing University Cancer Hospital

    Chongqing, 400044, China

  • City of Hope

    Duarte, California, 91010, United States

  • Hadassah Medical Center

    Jerusalem, 9112001, Israel

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Institut Curie

    Paris, 75005, France

  • Institut Universitaire du cancer de Toulouse-Oncopole

    Toulouse, 31059, France

  • Institut de Cancerologie Strasbourg Europe ICANS

    Strasbourg, 67033, France

  • Linear Clinical Research Ltd

    Nedlands, 6009, Australia

  • Macquarie University Hospital

    Macquarie University, 2109, Australia

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • National Cancer Center Hospital East

    Kashiwa, 277 8577, Japan

  • Odense University Hospital

    Odense, 5000, Denmark

  • Rigshospitalet

    Copenhagen, 2100, Denmark

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • Scientia Clinical Research

    Randwick, 2031, Australia

  • Seattle Cancer Care Alliance

    Seattle, Washington, 98109, United States

  • Sun Yat Sen University Cancer Center

    Guangzhou, 510060, China

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, 64239, Israel

  • Texas Transplant Institute

    San Antonio, Texas, 78229, United States

  • The Alfred Hospital

    Melbourne, 3004, Australia

  • The Cancer Institute Hospital of JFCR

    Tokyo, 135 8550, Japan

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Tianjin cancer hospital

    Tianjin, 300060, China

  • Union Hospital Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, 430030, China

  • Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz

    Gdansk, 80 214, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.